Manufacturing Potency Problems Drive Rise In Recalls During 2002
Executive Summary
An increase in potency-related manufacturing problems contributed to a rise in recalls during 2002
You may also be interested in...
Wyeth Estrogens GMP Surveillance Will Address Dissolution Issues
Wyeth is initiating a testing program to address dissolution issues with conjugated estrogens used in the company's lower-dose Prempro hormone replacement therapy
FDA GMP Initiative Shifts Warning Letter Review Back To Agency Centers
The Center for Drug Evaluation & Research will begin reviewing GMP warning letters March 1 as part of an FDA initiative to create a risk-based approach to pharmaceutical manufacturing
Drug Recalls Prompted By FDA Findings Accounted For 60% Of Total In 2000
A majority of drug product recalls conducted over the last two years have been initiated due to FDA inspection and sample findings rather than findings by the company.